Tufts Clinical and Translation Science Institute (UL1)

塔夫茨临床与翻译科学研究所 (UL1)

• 批准号: 7941329
• 负责人: Harry P. Selker
• 金额: $ 14.35万
• 依托单位: TUFTS UNIVERSITY BOSTON
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-05-19 至 2013-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7941329
• 关键词: Tufts; Clinical; Translation; Science; Institute

Representing seven schools of Tufts University (Medicine, Dental Medicine, Nutrition, Engineering, Arts & Sciences, Veterinary Medicine, and Graduate Biomedical Sciences), eight Tufts affiliated hospitals (listed below), the Tufts Center for the Study of Drug Development, the USDA Human Nutrition Research Center on Aging at Tufts, and the Tufts New England Medical Center (Tufts-NEMC) Institute for Clinical Research and Health Policy Studies, to address the challenge of the CTSA initiative, we have determined to: a) Create a new home for translational clinical research (TCR) at Tufts University, a cross-University, cross-affiliate Tufts Translational Clinical Research Institute (TTCRI), headed by an international leader in CR who will report to the University Provost, b) Provide a coordinated infrastructure to facilitate the spectrum of TCR by responding to the nine focus areas specified in the CTSA RFA and by creating four additional unique programs built on special Tufts strenths that will both accelerate and enhance the impact of CR. c) Enhance and expand the "CR Portal" at Tufts-NEMC as a TTCRI-wide central resource and develop on-site smaller CR Portals at our affiliated hospitals, thereby providing services and fostering interdisciplinary research collaborations and facilitating entry of new investigators into TCR. d) Building on Tufts' leadership as the first institution in the U.S. with a PhD program in CR in a graduate school of biomedical science, we will add to our current four MS/PhD Concentrations (Clinical Investigation, Epidemiology/Biostatistics, Health Services and Outcomes Research, and Medical Informatics), base on Tufts special strengths, two new Concentrations: Evidence Based Medicine (EBM) and Bench to Bedside Translational Research (B2BTR). Also, through distance teaming innovations, we will extend our reach to fellows and junior faculty in Western Massachusetts and elsewhere, and our K12 cadre will include a CR junior faculty member at each of the other three major Tufts hospitals outside Boston in addition to Tufts-NEMC. Our T32 program will lead to a joint MD or DMD with an MS or PhD in CR, or in conjunction with an MS in either nutrition or biomedical engineering, a PhD in CR. Through all aspects of training, including short courses, we will support and instill the culture of cooperative interdisciplinary research. Building on current Tufts strengths, the activities of the TTCRI will help achieve the transformation sought by the CTSA, and its benefit the health of the public.

代表塔夫茨大学的七个学院(医学、 牙科医学、营养学、工程学、文理、兽医和研究生 生物医学科学)，8家塔夫茨附属医院(如下所列)，塔夫茨研究中心 药物开发，美国农业部塔夫茨衰老人体营养研究中心，以及塔夫茨新 英国医学中心(Tuft-NEMC)临床研究和卫生政策研究所 为了应对CTSA倡议的挑战，我们决心：a)为 塔夫茨大学的转化性临床研究(TCR)，一个跨大学、跨附属机构的塔夫茨大学 翻译临床研究所(TTCRI)，由CR领域的一位国际领导者领导，他将 向大学教务长报告，b)提供协调的基础设施，以促进 TCR，回应CTSA RFA中规定的九个重点领域，并创建另外四个 独特的计划建立在特殊的塔夫茨强度上，既可以加速又可以增强CR的影响。 C)加强和扩大塔夫茨-NEMC的“CR门户”，将其作为TTCRI范围内的中央资源，并制定 我们附属医院的现场较小的CR门户，从而提供服务和促进 跨学科研究合作，并促进新的研究人员进入TCR。D)大楼 关于塔夫茨大学作为美国第一所在美国研究生院开设CR博士课程的机构的领导力 生物医学，我们将在目前的四个MS/PHD浓度基础上增加(临床研究， 流行病学/生物统计学、卫生服务和结果研究以及医学信息学)，基础 关于塔夫茨的特殊优势，两个新的集中度：循证医学(EBM)和BASE TO 床边翻译研究(B2BTR)。此外，通过远程团队创新，我们将扩展 我们与马萨诸塞州西部和其他地方的研究员和初级教员以及我们的K12干部将 包括波士顿以外的其他三家主要塔夫茨医院各一名CR初级教员 除了塔夫茨-NEMC。我们的T32计划将导致MD或DMD与CR的硕士或博士学位相结合，或者 与营养学或生物医学工程学硕士学位相结合，获得CR博士学位。贯穿于一切 在培训方面，包括短期课程，我们将支持和灌输合作文化 跨学科研究。在塔夫茨现有优势的基础上，TTCRI的活动将有所帮助 实现CTSA所寻求的转型，并使其惠及公众健康。